Integra Lifesciences Hldgs Cp Financials
Integra Lifesciences Hldgs Cp (IART) reported $1.6B in revenue over the twelve months to Jun 30, 2026, up 1.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Stable sales masked a sharp margin collapse, while equity absorption exposed the business to earnings volatility.
From FY2024 to FY2025, revenue moved only from$1.61B to$1.64B , so volume was not the main story. Over the same period, gross margin fell from54.8% to50.9% , leaving less room for operating costs and pushing operating margin to-30.2% .
In FY2025, the cash outcome was far milder than the accounting loss: operating cash flow was
Liabilities reached
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Integra Lifesciences Hldgs Cp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Integra Lifesciences Hldgs Cp has an operating margin of -30.2%, meaning the company loses $30 on every $100 of revenue. This results in a profitability score of 15/100. This is down from 1.8% the prior year.
Integra Lifesciences Hldgs Cp's revenue grew a modest 1.5% year-over-year to $1.6B. This slow but positive growth earns a score of 42/100.
Integra Lifesciences Hldgs Cp has a moderate D/E ratio of 0.70. This balance of debt and equity financing earns a leverage score of 53/100.
With a current ratio of 2.54, Integra Lifesciences Hldgs Cp holds $2.54 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 70/100.
While Integra Lifesciences Hldgs Cp generated $50.4M in operating cash flow, capex of $81.4M consumed most of it, leaving -$31.1M in free cash flow. This results in a low score of 30/100, reflecting heavy capital investment rather than weak cash generation.
Integra Lifesciences Hldgs Cp posts a -49.5% return on equity (ROE), meaning it loses $50 for every $100 of shareholders' equity. This results in a returns score of 18/100. This is down from -0.4% the prior year.
Integra Lifesciences Hldgs Cp scores 0.71, below the 1.81 distress threshold. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Integra Lifesciences Hldgs Cp passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Integra Lifesciences Hldgs Cp reported a net loss of $516.8M while generating $50.4M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Integra Lifesciences Hldgs Cp reported an operating loss of $493.4M against $86.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Integra Lifesciences Hldgs Cp generated $1.6B in revenue in fiscal year 2025. This represents an increase of 1.5% from the prior year.
Integra Lifesciences Hldgs Cp's EBITDA was -$433.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 570.8% from the prior year.
Integra Lifesciences Hldgs Cp reported -$516.8M in net income in fiscal year 2025. This represents a decrease of 7389.9% from the prior year.
Integra Lifesciences Hldgs Cp earned -$6.74 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 7388.9% from the prior year.
Cash & Balance Sheet
Integra Lifesciences Hldgs Cp recorded an outflow of $31.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 224.4% from the prior year.
Integra Lifesciences Hldgs Cp held $235.0M in cash against $726.6M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Integra Lifesciences Hldgs Cp's gross margin was 50.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 3.9 percentage points from the prior year.
Integra Lifesciences Hldgs Cp's operating margin was -30.2% in fiscal year 2025, reflecting core business profitability. This is down 31.9 percentage points from the prior year.
Integra Lifesciences Hldgs Cp's net profit margin was -31.6% in fiscal year 2025, showing the share of revenue converted to profit. This is down 31.2 percentage points from the prior year.
Integra Lifesciences Hldgs Cp's ROE was -49.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 49.1 percentage points from the prior year.
Capital Allocation
Integra Lifesciences Hldgs Cp invested $99.0M in research and development in fiscal year 2025. This represents a decrease of 14.2% from the prior year.
Integra Lifesciences Hldgs Cp spent $221K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 99.6% from the prior year.
Integra Lifesciences Hldgs Cp invested $81.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 22.0% from the prior year.
IART Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $418.8M+6.8% | $391.9M-9.9% | $434.9M+8.2% | $402.1M-3.3% | $415.6M+8.6% | $382.7M-13.6% | $442.6M+16.2% | $380.8M |
| Cost of Revenue | $199.0M+13.8% | $174.9M-18.3% | $214.1M+9.7% | $195.1M-5.4% | $206.3M+9.6% | $188.2M-2.8% | $193.6M+7.2% | $180.6M |
| Gross Profit | $219.7M+1.3% | $217.0M-1.8% | $220.9M+6.7% | $207.0M-1.1% | $209.3M+7.7% | $194.4M-21.9% | $249.1M+24.4% | $200.2M |
| R&D Expenses | $24.3M+3.2% | $23.5M-5.2% | $24.8M+10.4% | $22.5M-16.8% | $27.0M+9.2% | $24.7M-20.8% | $31.2M+13.8% | $27.4M |
| SG&A Expenses | $172.4M-3.3% | $178.2M+5.3% | $169.3M+0.1% | $169.0M-6.0% | $179.9M-0.9% | $181.5M+1.7% | $178.5M+0.7% | $177.2M |
| Operating Income | $19.3M+68.1% | $11.5M-50.2% | $23.0M+95.9% | $11.8M+102.3% | -$512.7M-3208.2% | -$15.5M-143.5% | $35.6M+537.1% | -$8.2M |
| Interest Expense | $23.0M+2.4% | $22.5M-5.1% | $23.7M+4.2% | $22.7M+8.0% | $21.0M+11.8% | $18.8M-0.9% | $19.0M-2.0% | $19.4M |
| Income Tax | $262K-88.1% | $2.2M-63.3% | $6.0M+523.5% | -$1.4M+97.0% | -$46.9M-888.4% | -$4.7M-252.7% | $3.1M+132.1% | -$9.7M |
| Net Income | $4.5M+197.1% | -$4.6M-127.4% | -$2.0M+62.4% | -$5.4M+98.9% | -$484.1M-1813.9% | -$25.3M-229.9% | $19.5M+282.1% | -$10.7M |
| EPS (Diluted) | $0.06+200.0% | -$0.06-200.0% | -$0.02+71.4% | -$0.07+98.9% | -$6.31-1812.1% | -$0.33-232.0% | $0.25+278.6% | -$0.14 |
IART Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.6B-0.4% | $3.6B-0.7% | $3.6B-1.2% | $3.6B-0.6% | $3.7B-9.5% | $4.1B+0.4% | $4.0B-0.7% | $4.1B |
| Current Assets | $1.2B+1.7% | $1.2B+1.1% | $1.2B+1.4% | $1.1B+0.1% | $1.1B+3.2% | $1.1B+2.4% | $1.1B-1.6% | $1.1B |
| Cash & Equivalents | $214.4M-9.5% | $236.8M+0.7% | $235.0M+1.2% | $232.2M+6.5% | $217.9M-8.9% | $239.1M-3.0% | $246.4M+14.5% | $215.2M |
| Inventory | $492.0M-0.6% | $495.0M+0.5% | $492.7M+0.7% | $489.1M+5.2% | $465.1M+4.4% | $445.4M+3.8% | $429.1M-1.8% | $436.9M |
| Accounts Receivable | $267.2M+1.0% | $264.4M-5.2% | $278.8M+6.4% | $262.2M-7.9% | $284.5M+12.7% | $252.4M-7.3% | $272.4M+9.7% | $248.3M |
| Goodwill | $611.1M-0.3% | $613.2M-0.3% | $615.2M0.0% | $615.2M-0.2% | $616.4M-44.2% | $1.1B+0.8% | $1.1B-1.8% | $1.1B |
| Total Liabilities | $2.5B-0.6% | $2.5B-0.9% | $2.6B-1.9% | $2.6B-0.8% | $2.6B+4.0% | $2.5B+1.5% | $2.5B-2.0% | $2.5B |
| Current Liabilities | $330.9M-4.6% | $346.8M-23.9% | $456.0M+25.3% | $364.1M-60.8% | $929.8M+1.2% | $918.5M-0.4% | $922.1M+1.0% | $912.6M |
| Long-Term Debt | $707.2M-1.4% | $716.9M-1.3% | $726.6M-1.3% | $736.3M-1.3% | $745.9M-1.3% | $755.6M-0.6% | $760.5M-0.6% | $765.3M |
| Total Equity | $1.0B+0.1% | $1.0B-0.1% | $1.0B+0.6% | $1.0B-0.1% | $1.0B-31.9% | $1.5B-1.4% | $1.5B+1.6% | $1.5B |
| Retained Earnings | $423.3M+1.1% | $418.8M-1.1% | $423.4M-0.4% | $425.1M-1.3% | $430.5M-52.9% | $914.6M-2.7% | $939.9M+2.1% | $920.5M |
IART Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $22.8M+132.6% | $9.8M-17.0% | $11.8M-71.1% | $40.9M+358.6% | $8.9M+179.2% | -$11.3M-122.2% | $50.7M+125.7% | $22.5M |
| Capital Expenditures | $12.3M-17.1% | $14.8M-13.7% | $17.2M+13.6% | $15.2M-24.8% | $20.1M-30.3% | $28.9M-2.3% | $29.6M-0.2% | $29.6M |
| Free Cash Flow | $10.5M+308.0% | -$5.0M+6.5% | -$5.4M-121.0% | $25.8M+329.4% | -$11.2M+72.1% | -$40.2M-290.1% | $21.1M+395.2% | -$7.2M |
| Investing Cash Flow | -$43.3M-191.5% | -$14.8M+57.5% | -$34.9M-123.9% | -$15.6M+28.0% | -$21.6M+39.7% | -$35.9M-745.4% | -$4.2M+59.1% | -$10.4M |
| Financing Cash Flow | -$818K-109.9% | $8.3M-65.9% | $24.3M+337.6% | -$10.2M+51.5% | -$21.1M-159.8% | $35.4M+594.8% | -$7.2M+64.1% | -$19.9M |
| Share Buybacks | N/A | N/A | $0 | $0 | N/A | N/A | $2.5M | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
IART Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 52.5%-2.9pp | 55.4%+4.6pp | 50.8%-0.7pp | 51.5%+1.1pp | 50.4%-0.4pp | 50.8%-5.5pp | 56.3%+3.7pp | 52.6% |
| Operating Margin | 4.6%+1.7pp | 2.9%-2.4pp | 5.3%+2.4pp | 2.9% | -123.4% | -4.0%-12.1pp | 8.1%+10.2pp | -2.1% |
| Net Margin | 1.1%+2.3pp | -1.2%-0.7pp | -0.5%+0.9pp | -1.3% | -116.5% | -6.6%-11.0pp | 4.4%+7.2pp | -2.8% |
| Return on Equity | 0.4%+0.9pp | -0.4%-0.2pp | -0.2%+0.3pp | -0.5%+46.1pp | -46.6%-45.0pp | -1.7%-2.9pp | 1.3%+2.0pp | -0.7% |
| Return on Assets | 0.1%+0.3pp | -0.1%-0.1pp | -0.1%+0.1pp | -0.1%+13.1pp | -13.2%-12.6pp | -0.6%-1.1pp | 0.5%+0.7pp | -0.3% |
| Current Ratio | 3.60+0.2x | 3.38+0.8x | 2.54-0.6x | 3.14+1.9x | 1.230.0x | 1.210.0x | 1.170.0x | 1.20 |
| Debt-to-Equity | 0.680.0x | 0.690.0x | 0.700.0x | 0.710.0x | 0.72+0.2x | 0.500.0x | 0.490.0x | 0.50 |
| FCF Margin | 2.5%+3.8pp | -1.3%-0.1pp | -1.2%-7.6pp | 6.4%+9.1pp | -2.7%+7.8pp | -10.5%-15.3pp | 4.8%+6.7pp | -1.9% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Where Integra Lifesciences Hldgs Cp Ranks
Frequently Asked Questions
What is Integra Lifesciences Hldgs Cp's annual revenue?
Integra Lifesciences Hldgs Cp (IART) reported $1.6B in total revenue for fiscal year 2025. This represents a 1.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Integra Lifesciences Hldgs Cp's revenue growing?
Integra Lifesciences Hldgs Cp (IART) revenue grew by 1.5% year-over-year, from $1.6B to $1.6B in fiscal year 2025.
Is Integra Lifesciences Hldgs Cp profitable?
No, Integra Lifesciences Hldgs Cp (IART) reported a net income of -$516.8M in fiscal year 2025, with a net profit margin of -31.6%.
What is Integra Lifesciences Hldgs Cp's EBITDA?
Integra Lifesciences Hldgs Cp (IART) had EBITDA of -$433.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Integra Lifesciences Hldgs Cp have?
As of fiscal year 2025, Integra Lifesciences Hldgs Cp (IART) had $235.0M in cash and equivalents against $726.6M in long-term debt.
What is Integra Lifesciences Hldgs Cp's gross margin?
Integra Lifesciences Hldgs Cp (IART) had a gross margin of 50.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Integra Lifesciences Hldgs Cp's operating margin?
Integra Lifesciences Hldgs Cp (IART) had an operating margin of -30.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Integra Lifesciences Hldgs Cp's net profit margin?
Integra Lifesciences Hldgs Cp (IART) had a net profit margin of -31.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Integra Lifesciences Hldgs Cp's return on equity (ROE)?
Integra Lifesciences Hldgs Cp (IART) has a return on equity of -49.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Integra Lifesciences Hldgs Cp's free cash flow?
Integra Lifesciences Hldgs Cp (IART) recorded an outflow of $31.1M in free cash flow during fiscal year 2025. This represents a -224.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Integra Lifesciences Hldgs Cp's operating cash flow?
Integra Lifesciences Hldgs Cp (IART) generated $50.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Integra Lifesciences Hldgs Cp's total assets?
Integra Lifesciences Hldgs Cp (IART) had $3.6B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Integra Lifesciences Hldgs Cp's capital expenditures?
Integra Lifesciences Hldgs Cp (IART) invested $81.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Integra Lifesciences Hldgs Cp spend on research and development?
Integra Lifesciences Hldgs Cp (IART) invested $99.0M in research and development during fiscal year 2025.
What is Integra Lifesciences Hldgs Cp's current ratio?
Integra Lifesciences Hldgs Cp (IART) had a current ratio of 2.54 as of fiscal year 2025, which is generally considered healthy.
What is Integra Lifesciences Hldgs Cp's debt-to-equity ratio?
Integra Lifesciences Hldgs Cp (IART) had a debt-to-equity ratio of 0.70 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Integra Lifesciences Hldgs Cp's return on assets (ROA)?
Integra Lifesciences Hldgs Cp (IART) had a return on assets of -14.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Integra Lifesciences Hldgs Cp's Altman Z-Score?
Integra Lifesciences Hldgs Cp (IART) has an Altman Z-Score of 0.71, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Integra Lifesciences Hldgs Cp's Piotroski F-Score?
Integra Lifesciences Hldgs Cp (IART) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Integra Lifesciences Hldgs Cp's earnings high quality?
Integra Lifesciences Hldgs Cp (IART) reported a net loss of $516.8M while generating $50.4M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Integra Lifesciences Hldgs Cp cover its interest payments?
Integra Lifesciences Hldgs Cp (IART) reported an operating loss of $493.4M against $86.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Integra Lifesciences Hldgs Cp?
Integra Lifesciences Hldgs Cp (IART) scores 38 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.